Andreas Schlosser
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (14)
Supplementary Figure 1. Validation of HLA-I ligand tumor antigen candidates with synthetic peptidesSupplementary Figure 2. Validation of selected HLA-I ligand tumor antigen candidates identified in Mel-1 and Mel-3 with isotope-labeled peptidesSupplementary Figure 3. Frequency of nonC peptides detected in HLA-I.Supplementary Fig. 4. HLA-I allele binding motif of all patients included in the study.Supplementary Figure 5. A fraction of nonC-TL can be detected in publicly available immunopeptidomics datasets from human tumor biopsiesSupplementary Figure 6. Evaluation of pre-existing T-cell responses to candidate tumor antigens in cancer patientsSupplementary Figure 7. Enrichment of antigen-specific T cells from cancer patients by flow cytometry-based sorting.Supplementary Figure 8. Deconvolution of peptide pools containing recognized CGA or melanoma-associated antigens.Supplementary Figure 9. Functional avidity and specificity of neoantigen-specific T cells isolated from cancer patients.Supplementary Figure 10. HLA restriction element and recognition of autologous tumor cell lines by antigen-specific T cells isolated from cancer patients.SupplementaryFigure 11. Genomic location of the three immunogenic nonC-TL identified through IVS.Supplementary Figure 12. Recognition of the predicted ORFs encoding the immunogenic nonC-TL by TCR transduced cells.Supplementary Figure 13. Loss of recognition of TCL transfected with Cas9-sgRNA targeting the predicted 5’U-HOXC13 ORF.Supplementary Figure 14. Assessment of expression and translation of the immunogenic nonC-TL in human healthy cells.Supplementary Figure 15. NonC-TL are the main source of candidate tumor antigens identified by proteogenomics but tumor-reactive T cells preferentially recognize neoantigens derived from NSM.
Year:
2025
Purpose: Tumor antigens are central to antitumor immunity. Recent evidence suggests that peptides from noncanonical (nonC) aberrantly translated proteins can be presented on HLA-I by tumor cells. Here, we investigated the immunogenicity of nonC tumor HLA-I ligands (nonC-TL) to better understand their contribution to cancer immunosurveillance and their therapeutic applicability. Experimental Design: Peptides presented on HLA-I were identified in 9 patient-derived tumor cell lines from melanoma, gynecologic, and head and neck cancer through proteogenomics. A total of 507 candidate tumor antigens, including nonC-TL, neoantigens, cancer-germline, or melanocyte differentiation antigens, were tested for T-cell recognition of preexisting responses in patients with cancer. Donor peripheral blood lymphocytes (PBL) were in vitro sensitized against 170 selected nonC-TL to isolate antigen-specific T-cell receptors (TCR) and evaluate their therapeutic potential. Results: We found no recognition of the 507 nonC-TL tested by autologous ex vivo expanded tumor-reactive T-cell cultures while the same cultures demonstrated reactivity to mutated, cancer-germline, or melanocyte differentiation antigens. However, in vitro sensitization of donor PBL against 170 selected nonC-TL, led to the identification of TCRs specific to three nonC-TL, two of which mapped to the 5′ UTR regions of HOXC13 and ZKSCAN1 , and one mapping to a noncoding spliced variant of C5orf22C . T cells targeting these nonC-TL recognized cancer cell lines naturally presenting their corresponding antigens. Expression of the three immunogenic nonC-TL was shared across tumor types and barely or not detected in normal cells. Conclusions: Our findings predict a limited contribution of nonC-TL to cancer immunosurveillance but demonstrate they may be attractive novel targets for widely applicable immunotherapies. See related commentary by Fox et al., p. 2173
Year:
2025
The immunopeptidome is constantly monitored by T cells to detect foreign or aberrant HLA peptides. It is highly dynamic and reflects the current cellular state, enabling the immune system to recognize abnormal cellular conditions, such as those present in cancer cells. To precisely determine how changes in cellular processes, such as those induced by drug treatment, affect the immunopeptidome, quantitative immunopeptidomics approaches are essential. To meet this need, we developed a pulsed SILAC-based method for quantitative immunopeptidomics. Metabolic labeling with lysine, arginine, and leucine enabled isotopic labeling of nearly all HLA peptides across all allotypes (> 90% on average). We established a data analysis workflow that integrates the de novo sequencing-based tool Peptide-PRISM for comprehensive HLA peptide identification with MaxQuant for accurate quantification. We employed this strategy to explore the modulation of the immunopeptidome upon MAPK pathway inhibition (MAPKi) and to investigate alterations associated with early cellular responses to inhibitor treatment and acquired resistance to MAPKi. Our analyses demonstrated significant changes in the immunopeptidome early during MAPKi treatment and in the resistant state. Moreover, we identified putative tumor-specific cryptic HLA peptides linked to these processes that might represent exploitable targets for cancer immunotherapy. Synopsis We have developed a mass spectrometric method that allowed us to investigate the effects of common MAPK inhibitors on the immunopeptidome of melanoma cells. This approach has led to the discovery of new potential targets for cancer immunotherapy.
Year:
2024
Post- or co-translational N-terminal modifications of proteins influence their half-life as well as mediating protein sorting to organelles via cleavable N-terminal sequences that are recognized by the respective translocation machinery. Here, we provide an overview on the current modification state of the N-termini of over 4500 proteins from the model moss Physcomitrella (Physcomitrium patens) using a compilation of 24 N-terminomics datasets. Our data reveal distinct proteoforms and modification states and confirm predicted targeting peptide cleavage sites of 1144 proteins localized to plastids and the thylakoid lumen, to mitochondria, and to the secretory pathway. Additionally, we uncover extended N-terminal methylation of mitochondrial proteins. Moreover, we identified PpNTM1 (P. patens alpha N-terminal protein methyltransferase 1) as a candidate for protein methylation in plastids, mitochondria and the cytosol. These data can now be used to optimize computational targeting predictors, for customized protein fusions and their targeted localization in biotechnology, and offer novel insights into potential dual targeting of proteins. Key message Analysis of the N-terminome of Physcomitrella reveals N-terminal monomethylation of nuclear encoded, mitochondria-localized proteins. Graphical abstract
Year:
2024
Numerous roles for the Alk receptor tyrosine kinase have been described in Drosophila, including functions in the central nervous system (CNS), however the molecular details are poorly understood. To gain mechanistic insight, we employed Targeted DamID (TaDa) transcriptional profiling to identify targets of Alk signaling in the larval CNS. TaDa was employed in larval CNS tissues, while genetically manipulating Alk signaling output. The resulting TaDa data were analysed together with larval CNS scRNA-seq datasets performed under similar conditions, identifying a role for Alk in the transcriptional regulation of neuroendocrine gene expression. Further integration with bulk/scRNA-seq and protein datasets from larval brains in which Alk signaling was manipulated, identified a previously uncharacterized Drosophila neuropeptide precursor encoded by CG4577 as an Alk signaling transcriptional target. CG4577, which we named Sparkly (Spar), is expressed in a subset of Alk-positive neuroendocrine cells in the developing larval CNS, including circadian clock neurons. In agreement with our TaDa analysis, overexpression of the Drosophila Alk ligand Jeb resulted in increased levels of Spar protein in the larval CNS. We show that Spar protein is expressed in circadian (Clock) neurons, and flies lacking Spar exhibit defects in sleep and circadian activity control. In summary, we report a novel activity regulating neuropeptide precursor gene that is regulated by Alk signaling in the Drosophila CNS.
Year:
2024
Numerous roles for the Alk receptor tyrosine kinase have been described in Drosophila, including functions in the central nervous system (CNS), however the molecular details are poorly understood. To gain mechanistic insight, we employed Targeted DamID (TaDa) transcriptional profiling to identify targets of Alk signaling in the larval CNS. TaDa was employed in larval CNS tissues, while genetically manipulating Alk signaling output. The resulting TaDa data were analysed together with larval CNS scRNA-seq datasets performed under similar conditions, identifying a role for Alk in the transcriptional regulation of neuroendocrine gene expression. Further integration with bulk/scRNA-seq and protein datasets from larval brains in which Alk signaling was manipulated, identified a previously uncharacterized Drosophila neuropeptide precursor encoded by CG4577 as an Alk signaling transcriptional target. CG4577, which we named Sparkly (Spar), is expressed in a subset of Alk-positive neuroendocrine cells in the developing larval CNS, including circadian clock neurons. In agreement with our TaDa analysis, overexpression of the Drosophila Alk ligand Jeb resulted in increased levels of Spar protein in the larval CNS. We show that Spar protein is expressed in circadian (Clock) neurons, and flies lacking Spar exhibit defects in sleep and circadian activity control. In summary, we report a novel activity regulating neuropeptide precursor gene that is regulated by Alk signaling in the Drosophila CNS.
Year:
2024
The Supplementary Figures file includes Figures S1 to S13. Figure S1: Gating strategy for the evaluation of LSC frequencies pre and post enrichment. Figure S2: Amino acid distribution within LSC and AML bulk immunopeptidomes. Figure S3: HLA class I immunopeptidomics. Figure S4: Abundance of AML- and AML/LSC-associated HLA class I ligands within the immunopeptidome. Figure S5: Identification of AML- and AML/LSC-associated HLA class II antigen targets by comparative immunopeptidome profiling. Figure S6: Abundance of AML- and AML/LSC-associated HLA class II peptides within the immunopeptidome. Figure S7: Spectral validation of HLA class I-restricted AML- and AML/LSC-associated peptides. Figure S8: Spectral validation of HLA class II-restricted AML- and AML/LSC-associated peptides. Figure S9: Magnitude and functionality of in vitro primed CD8+ T cells. Figure S10: Characterization of memory T cell responses detected in ELISpot assays. Figure S11: Further characterization of HLA class II-restricted antigens. Figure S12: In-depth characterization and phenotyping of HLA class II AML/LSC-specific CD4+ T cells by single-cell RNA sequencing and multi-color flow cytometry. Figure S13: Impact of immunopeptidome diversity and peptide-specific immune responses on patient survival.
Year:
2024
The Supplementary Tables file includes Tables S1 to S15. Table S1: Frequencies of CD34+CD38- LSCs within primary AML patient samples. Table S2: Immunopeptidomics cohort overview. Table S3: Patient characteristics of AML immunopeptidomics cohort. Table S4: AML- and AML/LSC-associated HLA class I targets. Table S5: AML/LSC shared HLA class I-presented antigens. Table S6: AML- and AML/LSC-associated HLA class II peptide, protein, and hotspot targets. Table S7: AML/LSC shared HLA class II-presented peptide targets. Table S8: Recurrent AML mutations included in neoepitope screening. Table S9: Characteristics of AML patient samples used for T cell-based assays. Table S10: Characteristics of HV samples used for T cell-based assays. Table S11: Immunopeptidome diversity according to demographics and disease characteristics. Table S12: Impact of demographics and disease characteristics on patient outcome in the immunopeptidome survival analysis group. Table S13: Patient characteristics of immunopeptidome survival analysis group. Table S14: Patient characteristics of immune response survival analysis group. Table S15: Impact of demographics and hematopoietic stem cell transplantation on patient outcome in the immune response survival group.
Year:
2024
The Supplementary Figures file includes Figures S1 to S13. Figure S1: Gating strategy for the evaluation of LSC frequencies pre and post enrichment. Figure S2: Amino acid distribution within LSC and AML bulk immunopeptidomes. Figure S3: HLA class I immunopeptidomics. Figure S4: Abundance of AML- and AML/LSC-associated HLA class I ligands within the immunopeptidome. Figure S5: Identification of AML- and AML/LSC-associated HLA class II antigen targets by comparative immunopeptidome profiling. Figure S6: Abundance of AML- and AML/LSC-associated HLA class II peptides within the immunopeptidome. Figure S7: Spectral validation of HLA class I-restricted AML- and AML/LSC-associated peptides. Figure S8: Spectral validation of HLA class II-restricted AML- and AML/LSC-associated peptides. Figure S9: Magnitude and functionality of in vitro primed CD8+ T cells. Figure S10: Characterization of memory T cell responses detected in ELISpot assays. Figure S11: Further characterization of HLA class II-restricted antigens. Figure S12: In-depth characterization and phenotyping of HLA class II AML/LSC-specific CD4+ T cells by single-cell RNA sequencing and multi-color flow cytometry. Figure S13: Impact of immunopeptidome diversity and peptide-specific immune responses on patient survival.
Year:
2024
The Supplementary Tables file includes Tables S1 to S15. Table S1: Frequencies of CD34+CD38- LSCs within primary AML patient samples. Table S2: Immunopeptidomics cohort overview. Table S3: Patient characteristics of AML immunopeptidomics cohort. Table S4: AML- and AML/LSC-associated HLA class I targets. Table S5: AML/LSC shared HLA class I-presented antigens. Table S6: AML- and AML/LSC-associated HLA class II peptide, protein, and hotspot targets. Table S7: AML/LSC shared HLA class II-presented peptide targets. Table S8: Recurrent AML mutations included in neoepitope screening. Table S9: Characteristics of AML patient samples used for T cell-based assays. Table S10: Characteristics of HV samples used for T cell-based assays. Table S11: Immunopeptidome diversity according to demographics and disease characteristics. Table S12: Impact of demographics and disease characteristics on patient outcome in the immunopeptidome survival analysis group. Table S13: Patient characteristics of immunopeptidome survival analysis group. Table S14: Patient characteristics of immune response survival analysis group. Table S15: Impact of demographics and hematopoietic stem cell transplantation on patient outcome in the immune response survival group.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2022
Collaborators (26)
Melanie Märklin
Reserach group leader
University Hospital Tübingen
Alena Gros
Group Leader
Vall d'Hebron Institute of Oncology
Elke Rücker-Braun
University Hospital Carl Gustav Carus
Daniel Lang
-
Yacine Maringer
University of Tuebingen
Margret Shirinian
Tenured Associate Professor
American University of Beirut
Claudia Lengerke
Vice Dean
University Hospital Tübingen
Jens Bauer
Postdoc – Head of Research
Universitätsklinikum Tübingen
Natalie Köhler
Junior Professor
University Medical Center Freiburg
Ralf Reski
Distinguished Professor, Head
Albert-Ludwigs-Universität Freiburg
Ignacio Matos
Clinica Universidad de Navarra
Bastian Schilling
Director and Chair
Goethe University Frankfurt
Christian Wegener
Professor of Neurogenetics
Julius-Maximilians-Universität Würzburg Biozentrum
Ravindra Majeti
Stanford University
Juliane S. Walz
University Hospital Tübingen
Ruth H. Palmer
Professor
University of Gothenburg
Annette Paschen
University Hospital Essen
Sanjay Kumar Sukumar
Project student at Prof. Ruth Palmer's Group
University of Gothenburg
Sebastian Hoernstein
Senior Scientist
University of Freiburg
Helmut R. Salih
University Hospital Tübingen
Elena Garralda
Director
-
Annika Nelde
University Hospital Tübingen
Florian Erhard
Chair of Computational Immunology
University of Regensburg
Dick Nässel
Stockholm University
August Vidal
Professor Associat Mèdic
University of Barcelona
Jared Gartner
National Institutes of Health
Make your next move.
Prepare your application
Review drafts before you send them.